

MYRIAD GENETICS INC  
Form 8-K  
August 16, 2007

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): 08/16/2007**

**Myriad Genetics, Inc.**

(Exact name of registrant as specified in its charter)

**Commission File Number: 0-26642**

**Delaware**  
(State or other jurisdiction of  
incorporation)

**87-0494517**  
(IRS Employer  
Identification No.)

**320 Wakara Way**  
Salt Lake City, Utah 84108  
(Address of principal executive offices, including zip code)

**801-584-3600**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Edgar Filing: MYRIAD GENETICS INC - Form 8-K

Information to be included in the report

**Item 8.01. Other Events**

On August 16, 2007, Myriad Genetics, Inc. announced that it has initiated a third Phase 2 human clinical trial of its therapeutic candidate, Azixa(TM) (MPC-6827), in patients with non-small-cell lung cancer that has spread to the brain. The information in the press release dated August 16, 2007 is incorporated herein by reference and attached to this Current Report on Form 8-K as Exhibit 99.1 hereto.

**Item 9.01. Financial Statements and Exhibits**

(d)

Exhibit

Number      Description

99.1            The Registrant's press release dated August 16, 2007 concerning the initiation of a third Phase 2 human clinical trial of Azixa in patients with non-small-cell lung cancer that has spread to the brain.

---

**Signature(s)**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Myriad Genetics, Inc.

Date: August 16, 2007

By: /s/ Peter D. Meldrum

---

Peter D. Meldrum  
President and Chief Executive Officer

**Exhibit Index**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
EX-99.1	The Registrant's press release dated August 16, 2007 concerning the initiation of a third Phase 2 human clinical trial of Azixa in patients with non-small-cell lung cancer that has spread to the brain.